CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street

Group 1 - CRISPR Therapeutics AG (NASDAQ:CRSP) is included in the ARK Invest Stock Portfolio as one of the top 10 stock picks for 2026, with a stake value exceeding $551 million as of Q4 2025 [1] - The company currently holds a Moderate Buy rating from analysts, with an average share price upside of 17% as of March 4 [1] - Truist Financial analyst Joon Lee reaffirmed a Buy rating for CRISPR Therapeutics on March 2, indicating continued analyst interest [1] Group 2 - Chardan Capital raised its price target for CRISPR Therapeutics AG to $76 from $74 while maintaining a Buy rating, following the company's business update and Q4 results announcement on February 12 [2] - Analyst Geulah Livshits from Chardan noted the positive momentum in the company's siRNA therapies and vivo cardiovascular editing, along with advancements in various clinical and preclinical programs [3] - Following the Q4 report, TD Cowen increased its price target to $45 from $40, maintaining a Hold rating, and highlighted strong momentum in CASGEVY, which generated quarterly revenue of $54 million and full-year revenue of $116 million [4] Group 3 - CRISPR Therapeutics AG focuses on developing CRISPR/Cas9-based therapeutics aimed at treating genetically-defined diseases and engineering advanced cellular therapies [5]